Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced on September 8, 2026, that Thomas Englese has been promoted to Chief Commercial Officer, effective immediately. Mr. Englese previously served as the Company’s Executive Vice President, Commercial Operations, a role he assumed in September 2024.
In his new capacity, Mr. Englese will direct sales, marketing, market access, and commercial operations for Tonix’s marketed portfolio. These products include TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia, as well as Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) for the treatment of acute migraine in adults.
CEO Seth Lederman, M.D., stated that Mr. Englese has been instrumental in the formation of Tonix’s commercial organization and the launch of TONMYA. Dr. Lederman noted that the promotion marks an important milestone for the Company as it seeks to expand access to TONMYA for more fibromyalgia patients.
Mr. Englese brings extensive experience in building and scaling commercial organizations. Prior to joining Tonix, he served as Chief Commercial Officer of Tris Pharmaceuticals, where he managed the ADHD global brand business. He also served as Chief Commercial Officer of Aziyo, responsible for the cardiac and soft tissue business, and held leadership roles at Mallinckrodt plc and Baxter Healthcare International.
